Development of stabilised mixtures of fluorescentally labelled antibodies in a single test pack for flow cytometry (Q12098)

From EU Knowledge Graph
Revision as of 15:11, 22 October 2020 by DG Regio (talk | contribs) (‎Created claim: summary (P836): The aim of the project is to increase the R & D capacity of Exbio Praha, a.s. in the area of stabilised mixtures of fluorescence-labelled antibodies in a single-test packaging for flow cytometry. The expansion of VIK will strengthen the company’s position in the world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in health care and will allow further expansion and diversification of products mainly...)
Jump to navigation Jump to search
Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Development of stabilised mixtures of fluorescentally labelled antibodies in a single test pack for flow cytometry
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    11,165,000.0 Czech koruna
    0 references
    446,600.0 Euro
    10 January 2020
    0 references
    22,330,000.0 Czech koruna
    0 references
    893,200.0 Euro
    10 January 2020
    0 references
    50 percent
    0 references
    31 December 2020
    0 references
    EXBIO Praha, a.s.
    0 references
    0 references

    49°59'0.49"N, 14°30'9.11"E
    0 references
    25250
    0 references
    Cílem projektu je zvýšení kapacit vlastního VaV společnosti EXBIO Praha, a.s. v oblasti stabilizovaných směsí fluorescenčně značených protilátek v jednotestovém balení pro průtokovou cytometrii. Rozšíření VIK posílí postavení společnosti na světovém obchodu s monoklonálními protilátkami, jejich deriváty a diagnostickými soupravami pro klinickou diagnostiku ve zdravotnictví a umožní další rozšíření a diversifikaci produktů především do zdravotnické diagnostiky. a. (Czech)
    0 references
    The aim of the project is to increase the R & D capacity of Exbio Praha, a.s. in the area of stabilised mixtures of fluorescence-labelled antibodies in a single-test packaging for flow cytometry. The expansion of VIK will strengthen the company’s position in the world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in health care and will allow further expansion and diversification of products mainly into medical diagnostics. a. (English)
    22 October 2020
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/17_165/0015522
    0 references